logo-loader
viewRedfund Capital Corp.

Redfund Capital Corp grows client list with cannabis edibles infusions brand, Biolog Inc

Biolog has developed a patented system to infuse food and beverages with cannabis

1529681832_DSC00540_preview.jpg
Biolog will use the financing to accelerate its product schedule

Redfund Capital Corp (CSE:COPR, OTC:PNNRF, Frankfurt:O3X4) announced today that it is adding a new client to its budding client list: Biolog Inc. 

Biolog has developed a patented system to infuse food and beverages with cannabis, which provides enhanced bioavailability — the amount of a substance that becomes available — and reduced onset times.

“Redfund Capital is specifically focused on funding cannabis-related companies that have strong growth potential and that is exactly what we see in Biolog,” said chief executive officer Meris Kott.

“Biolog’s products were specifically designed to solve the inconsistencies within the edible cannabis market and we are pleased to welcome them to the Redfund portfolio of companies.”

READ: ‘Cannabis 2.0 is here’: Redfund Capital fires up to serve maturing cannabis market

The Biolog products are powered by Lexaria Bioscience Corp's (CSE:LXX) DehydraTECHTM technology, under a license agreement announced earlier this year.

“The financing from Redfund will allow us to accelerate our product schedule. The patented process we deploy allows us to produce products that normal consumers or professional processors can utilize to turn virtually any food into a cannabis edible that is accurately dosed with highly bioavailable cannabinoids," said Bruce Bauer, chief executive officer of Biolog. 

"While we will enter the marketplace with a strong patent portfolio, our internally developed testing regime, which is based on some of the most advanced laboratory equipment in the market, will ensure that consumers and processors can use our products with confidence.”

Technology protected by patents

The Biolog technology is protected by multiple patents and trade secrets, including a patent portfolio licensed from Lexaria, enabling consumers and processors to precisely dose almost any food or beverage with either cannabidiol (CBD), tetrahydrocannabinol (THC) or any combination of these or other cannabinoids.

The company said CBD edibles manufactured with Biolog's technology could offer improvements in bioavailability of up to 500%, while also reducing onset times for psychoactive effects from tetrahydrocannabinol (THC) to as fast as 15 to 20 minutes. 

Quick facts: Redfund Capital Corp.

Price: 0.1 CAD

CSE:LOAN
Market: CSE
Market Cap: $5.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redfund Capital Corp. named herein, including the promotion by the Company of Redfund Capital Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redfund Capital partner Cannamerx International launches Hemp/CBD Auction...

Redfund Capital Corp (CSE:LOAN) (OTCMKTS:PNNRF) CEO Meris Kott tells Proactive Investors the cannabis-focused financier has formed a strategic alliance with hemp-auction platform Cannabis Mercantile Exchange that launches today. Kott says Redfund will help with financing and building...

on 21/3/19

2 min read